Our Company

Wim Souverijns, PhD

Chief Commercial Officer

Wim Souverijns brings nearly 20 years of experience in the pharmaceutical industry. November 1, 2018 he joined ObsEva as Chief Commercial Office out of the Geneva HQ responsible for the commercialization of ObsEva’s women’s health product portfolio.

Prior to joining ObsEva, Wim spent 11 years at Celgene where he contributed to the successful built out of Celgene’s product portfolio in diverse strategic (European & Global Marketing), as well as operational (General Manager for the Nordics and the UK & Ireland) roles. Most recently he served as the head of Global Marketing for Hematology & Oncology out of Summit, New Jersey. He developed a broad pharmaceutical background through various international assignments at PwC Consulting (1999-2003) and in different market access leadership roles at Amgen (2003-2007), both in the European headquarter in Luzern, Switzerland, as well as at the global level out of Thousand Oaks, California. He started off his career working for CTG (1997-1999), an IT services company, in Brussels, Belgium.

Wim studied as a bio-engineer at the KU Leuven, Belgium, and obtained a PhD  from the same institute.

Are you sure you want to leave ObsEva.com?

We’re sorry to see you go. Choose one of the following actions to stay on the site or leave.

Continue to link

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue

Disclaimer

Note that the following information contains information on investigational medicinal products. These products have not yet been approved for marketing by the European Medicines Agency or the U.S. Food and Drug Administration and are still under development. Further additional investigations may be needed in order for the marketing authorization to be granted, which grant may depend on a variety of factors and is not guaranteed. Click on “return” if you do not wish to receive such information. By clicking on “continue” you acknowledge that you wish to receive scientific information on our investigational products.

Continue